medvisМедицинская визуализацияMedical Visualization1607-07632408-9516RDS-Media Ltd.10.24835/1607-0763-2018-1-57-67medvis-508Research ArticleБРЮШНАЯ ПОЛОСТЬABDOMENПЭТ/КТ В ДИАГНОСТИКЕ РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ: ОБЗОР ЛИТЕРАТУРЫPET/CT IN THE DIAGNOSIS OF PANCREATIC CANCER: LITERATURE REVIEWТулинП. Е.TulinP. E.

Тулин Павел Евгеньевич – врач отделения позитронной эмиссионной томографии НИИ КиЭР.

115478 Москва, Каширское шоссе, д. 23, +7-916-870-99-13

Pavel E. Tulin – medical doctor of PET department.

115478, Moscow, Kashirskoe shosse, 23, +7-916-870-99-13

480pol@mail.ruДолгушинМ. Б.DolgushinM. B.

Долгушин Михаил Борисович – доктор медицинских наук, профессор, заведующий отделением позитронной эмиссионной томографии НИИ КиЭР.

Москва

Mikhail B. Dolgushin – doct. of med. sci., professor, head of PET department.

Moscow

НевзоровД. И.NevzorovD. I.

Невзоров Денис Игоревич – инженер-радиохимик отделения позитронной эмиссионной томографии НИИ КиЭР.

Москва

Denis I. Nevzorov – engineer of PET department.

Moscow

КочергинП. В.KocherginP. V.

Кочергин Павел Владимирович – медицинский физик отделения позитронной эмиссионной томографии НИИ КиЭР.

Москва

Pavel V. Kochergin – medical physicist of PET department.

Moscow

ПатюткоЮ. И.PatyutkoYu. I.

Москва. Патютко Юрий Иванович – доктор медицинских наук, профессор, ведущий научный сотрудник отделения хирургического лечения опухолей печени и поджелудочной железы НИИ КО.

Москва. 

Yurii I. Patyutko – doct. of med. sci., professor, medical doctor of surgical department of treatment of hepatic and pancreatic tumors.

Moscow

ФГБУ “Национальный медицинский исследовательский центр им. Н.Н. Блохина” Минздрава РоссииРоссияN.N. Blokhin Russian Cancer Research CenterRussian Federation201828022018015767Copyright © Тулин П.Е., Долгушин М.Б., Невзоров Д.И., Кочергин П.В., Патютко Ю.И., 20182018Тулин П.Е., Долгушин М.Б., Невзоров Д.И., Кочергин П.В., Патютко Ю.И.Tulin P.E., Dolgushin M.B., Nevzorov D.I., Kochergin P.V., Patyutko Y.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://medvis.vidar.ru/jour/article/view/508

Рак поджелудочной железы обладает неблагоприятным прогнозом выживаемости, зачастую из-за установления диагноза на поздних сроках заболевания, когда опухоль является неоперабельной. Раннее стадирование опухолевого процесса способно изменить тактику лечения и повлиять на выживаемость пациентов. Целью данного обзора являются анализ данных литературы по диагностике рака поджелудочной железы и уточнение роли ПЭТ/КТ с различными радиофармпрепаратами.

Pancreatic cancer has a poor prognosis, often because most pancreatic neoplasms are found to be unresectable at diagnosis. Early staging of the tumor process can change the tactics of treatment and affect the survival of patients. The purpose of this review is to provide an overview of pancreatic cancer and the role of modern imaging in its diagnosis with an emphasis on PET/CT with a various radiopharmaceuticals.

ПЭТ/КТ18F-фтордезоксиглюкоза68Ga-DOTAрак поджелудочной железынейроэндокринные опухоли поджелудочной железыPET/CT18F-fluorodeoxyglucose68Ga-DOTApancreatic cancerneuroendocrine tumors of the pancreasReferencesFerlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D., Forman D., Bray F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. DOI: 10.1002/ijc.29210.Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D., Forman D., Bray F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. 2013. DOI: 10.1002/ijc.29210.Hidalgo M., Cascinu S., Kleeff J., Labianca R., Löhr J., Neoptolemos J., Real F., Van Laethem J., Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2013; 15: 8–18. DOI: 10.1016/j.pan.2014.10.001.Hidalgo M., Cascinu S., Kleeff J., Labianca R., Löhr J., Neoptolemos J., Real F., Van Laethem J., Heinemann V. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2013; 15: 8–18. DOI: 10.1016/j.pan.2014.10.001.Solcia E., Capella C., Klöppel G. Tumors of the Pancreas: AFIP Atlas of Tumor Pathology, 3rd series, fascicle 20. Washington, DC: Armed Forces Institute of Pathology. 1997: 14–18.Solcia E., Capella C., Klöppel G. Tumors of the Pancreas: AFIP Atlas of Tumor Pathology, 3rd series, fascicle 20. Washington, DC: Armed Forces Institute of Pathology. 1997: 14–18.Malvezzi M., Carioli G., Bertuccio P., Rosso T., Boffetta P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann. Oncol. 2016; 27: 725–731. DOI: 10.1093/annonc/mdw022.Malvezzi M., Carioli G., Bertuccio P., Rosso T., Boffetta P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann. Oncol. 2016; 27: 725–731. DOI: 10.1093/annonc/mdw022.Chari S.T., Leibson C.L., Rabe K.G., Timmons L.J., Ransom J., De Andrade M., Petersen G.M. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134 (1): 95–101. DOI: 10.1053/j.gastro.2007.10.040.Chari S.T., Leibson C.L., Rabe K.G., Timmons L.J., Ransom J., De Andrade M., Petersen G.M. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134 (1): 95–101. DOI: 10.1053/j.gastro.2007.10.040.Bosetti C., Lucenteforte E., Silverman D.T., Petersen G., Bracci P.M., Ji B.T. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann. Oncol. 2012; 23 (7): 1880–1888. DOI: 10.1093/annonc/mdr541.Bosetti C., Lucenteforte E., Silverman D.T., Petersen G., Bracci P.M., Ji B.T. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann. Oncol. 2012; 23 (7): 1880–1888. DOI: 10.1093/annonc/mdr541.Duell E. J., Lucenteforte E., Olson S. H., Bracci P. M., Li D., Risch H. A. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (Panс4). Ann. Oncol. 2012; 23 (11): 140. DOI:10.1093/annonc/mds140.Duell E. J., Lucenteforte E., Olson S. H., Bracci P. M., Li D., Risch H. A. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (Panс4). Ann. Oncol. 2012; 23 (11): 140. DOI:10.1093/annonc/mds140.Artinyan A., Soriano P. A., Prendergast C., Low T., Ellenhorn J.D., Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB. 2008; 10 (5): 371–376. DOI: 10.1080/13651820802291233.Artinyan A., Soriano P. A., Prendergast C., Low T., Ellenhorn J.D., Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB. 2008; 10 (5): 371–376. DOI: 10.1080/13651820802291233.Gospodarowicz M.K., Brierley J.D., Wittekind C. TNM classification of malignant tumours. 2017: 94–95.Gospodarowicz M.K., Brierley J.D., Wittekind C. TNM classification of malignant tumours. 2017: 94–95.Khalid A., Dewitt J., Ohori N. P., Chen J. H., Fasanella K. E., Sanders U. EUS-FNA mutational analysis in differentiating autoimmune pancreatitis and pancreatic cancer. Pancreatology. 2011; 11 (5): 482–486. DOI: 10.1159/000331505.Khalid A., Dewitt J., Ohori N. P., Chen J. H., Fasanella K. E., Sanders U. EUS-FNA mutational analysis in differentiating autoimmune pancreatitis and pancreatic cancer. Pancreatology. 2011; 11 (5): 482–486. DOI: 10.1159/000331505.Conrad C., Fernández-del Castillo C. Preoperative evaluation and management of the pancreatic head mass. J. Surg. Oncol. 2013; 107 (1): 23–32. DOI: 10.1002/jso.23165.Conrad C., Fernández-del Castillo C. Preoperative evaluation and management of the pancreatic head mass. J. Surg. Oncol. 2013; 107 (1): 23–32. DOI: 10.1002/jso.23165.Giovannini M. Contrast-enhanced and 3-dimensional endoscopic ultrasonography. Gastroenterol. Clin. N. Am. 2010; 39 (4): 845–858. DOI: 10.1016/j.gtc.2010.08.027.Giovannini M. Contrast-enhanced and 3-dimensional endoscopic ultrasonography. Gastroenterol. Clin. N. Am. 2010; 39 (4): 845–858. DOI: 10.1016/j.gtc.2010.08.027.D’Onofrio M., Biagioli E., Gerardi C., Canestrini S., Rulli E., Crosara S. Diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced endoscopic ultrasound (ECEUS) for the differentiation of pancreatic lesions: a systematic review and meta-analysis. Ultraschall Med. – Eur. J. Ultrasound. 2014; 35 (6): 515–521. DOI: 10.1055/s-0034-1385068.D’Onofrio M., Biagioli E., Gerardi C., Canestrini S., Rulli E., Crosara S. Diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced endoscopic ultrasound (ECEUS) for the differentiation of pancreatic lesions: a systematic review and meta-analysis. Ultraschall Med. – Eur. J. Ultrasound. 2014; 35 (6): 515–521. DOI: 10.1055/s-0034-1385068.Kamisawa T., Wood L. D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016; 388 (10039): 73–85. DOI: 10.1016/S0140-6736(16)00141-0.Kamisawa T., Wood L. D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016; 388 (10039): 73–85. DOI: 10.1016/S0140-6736(16)00141-0.Karmazanovsky G., Fedorov V., Kubyshkin V., Kotchatkov A. Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom. Imaging. 2005; 30 (4): 488–500. DOI: 10.1007/s00261-004-0279-z.Karmazanovsky G., Fedorov V., Kubyshkin V., Kotchatkov A. Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom. Imaging. 2005; 30 (4): 488–500. DOI: 10.1007/s00261-004-0279-z.Ahn S.S., Kim M.J., Choi J.Y., Hong H.S., Chung Y.E., Lim J.S. Indicative findings of pancreatic cancer in prediagnostic CT. Eur. Radiol. 2009; 19 (10): 2448–2455. DOI: 10.1007/s00330-009-1422-6.Ahn S.S., Kim M.J., Choi J.Y., Hong H.S., Chung Y.E., Lim J.S. Indicative findings of pancreatic cancer in prediagnostic CT. Eur. Radiol. 2009; 19 (10): 2448–2455. DOI: 10.1007/s00330-009-1422-6.Li H., Zeng M.S., Zhou K.R., Lou W. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J. Comput. Assist. Tomogr. 2005; 29 (2): 170–175.Li H., Zeng M.S., Zhou K.R., Lou W. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J. Comput. Assist. Tomogr. 2005; 29 (2): 170–175.d'Assignies G., Couvelard A., Bahrami S., Vullierme M.P., Hammel P., Hentic O. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors1. Radiology. 2009; 250 (2): 407–416. DOI: 10.1148/radiol.2501080291.d'Assignies G., Couvelard A., Bahrami S., Vullierme M.P., Hammel P., Hentic O. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors1. Radiology. 2009; 250 (2): 407–416. DOI: 10.1148/radiol.2501080291.Нерестюк Я.И. КТ-перфузия при опухолях поджелудочной железы. Медицинская визуализация. 2015; 3: 57–67. Nerestjuk Ja.I. CT-perfusion in tumors of the pancreas. Medical Visualization. 2015; 3: 57–67. (In Russian)Нерестюк Я.И. КТ-перфузия при опухолях поджелудочной железы. Медицинская визуализация. 2015; 3: 57–67. Nerestjuk Ja.I. CT-perfusion in tumors of the pancreas. Medical Visualization. 2015; 3: 57–67. (In Russian)Bipat S., Phoa S.S.S., van Delden O.M., Bossuyt P.M., Gouma D.J., Laméris J.S. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J. Comput. Assist. Tomogr. 2005; 29 (4): 438–445.Bipat S., Phoa S.S.S., van Delden O.M., Bossuyt P.M., Gouma D.J., Laméris J.S. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J. Comput. Assist. Tomogr. 2005; 29 (4): 438–445.Park H.S., Lee J.M., Choi H.K., Hong S.H., Han J.K., Choi B.I. Preoperative evaluation of pancreatic cancer: Comparison of gadolinium enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J. Magn. Reson. Imaging. 2009; 30 (3): 586–595. DOI: 10.1002/jmri.21889.Park H.S., Lee J.M., Choi H.K., Hong S.H., Han J.K., Choi B.I. Preoperative evaluation of pancreatic cancer: Comparison of gadolinium enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J. Magn. Reson. Imaging. 2009; 30 (3): 586–595. DOI: 10.1002/jmri.21889.Kim J.H., Park S.H., Yu E.S., Kim M.H., Kim J., Byun J.H., Lee M.G. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010; 257 (1): 87–96. DOI: 10.1148/radiol.10100015.Kim J.H., Park S.H., Yu E.S., Kim M.H., Kim J., Byun J.H., Lee M.G. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010; 257 (1): 87–96. DOI: 10.1148/radiol.10100015.Adamek H.E., Albert J., Breer H., Weitz M., Schilling D., Riemann J. F. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000; 356 (9225): 190–193. DOI: 10.1016/S0140-6736(00)02479-X.Adamek H.E., Albert J., Breer H., Weitz M., Schilling D., Riemann J. F. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet. 2000; 356 (9225): 190–193. DOI: 10.1016/S0140-6736(00)02479-X.Raman S.P., Horton K.M., Fishman E.K. Multimodality imaging of pancreatic cancer – computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 2012; 18 (6): 511–522. DOI: 10.1097/PPO.0b013e318274a461.Raman S.P., Horton K.M., Fishman E.K. Multimodality imaging of pancreatic cancer – computed tomography, magnetic resonance imaging, and positron emission tomography. Cancer J. 2012; 18 (6): 511–522. DOI: 10.1097/PPO.0b013e318274a461.Hruban R.H., Pitman M.B., Klimstra D.S. Tumors of the pancreas. Am. Registry Pathol. 2007; 6: 13–21. DOI: 10.1043/1543-2165-133.3.454.Hruban R.H., Pitman M.B., Klimstra D.S. Tumors of the pancreas. Am. Registry Pathol. 2007; 6: 13–21. DOI: 10.1043/1543-2165-133.3.454.Гарматина О.Ю. Современные методы неинвазивной визуализации желчевыводящих путей. Клінічна та експериментальна патологія. 2014; 13 (2): 199–204. Garmatina O.Ju. Modern methods of non-invasive imaging of the biliary tract. Klinichna ta eksperimental'na patologija. 2014; 13 (2): 199–204. (In Russian)Гарматина О.Ю. Современные методы неинвазивной визуализации желчевыводящих путей. Клінічна та експериментальна патологія. 2014; 13 (2): 199–204. Garmatina O.Ju. Modern methods of non-invasive imaging of the biliary tract. Klinichna ta eksperimental'na patologija. 2014; 13 (2): 199–204. (In Russian)Zakharova O.P., Karmazanovsky G.G., Egorov V.I. Pancreatic adenocarcinoma: Outstanding problems. Wld J. Gastrointest. Surg. 2012; 4 (5): 104. DOI: 10.4240/wjgs.v4.i5.104.Zakharova O.P., Karmazanovsky G.G., Egorov V.I. Pancreatic adenocarcinoma: Outstanding problems. Wld J. Gastrointest. Surg. 2012; 4 (5): 104. DOI: 10.4240/wjgs.v4.i5.104.Шима В., Кауэлблингер К. Аденокарцинома поджелудочной железы: выявление, определение стадии и дифференциальная диагностика. Медицинская визуализация. 2015; 5: 52–72. Shíma V., Kabelbinder K. Pancreatic adenocarcinoma: detection, stage determination and differential diagnosis. Medical Visualization. 2015; 5: 52–72. (In Russian)Шима В., Кауэлблингер К. Аденокарцинома поджелудочной железы: выявление, определение стадии и дифференциальная диагностика. Медицинская визуализация. 2015; 5: 52–72. Shíma V., Kabelbinder K. Pancreatic adenocarcinoma: detection, stage determination and differential diagnosis. Medical Visualization. 2015; 5: 52–72. (In Russian)Higashi T., Saga T., Nakamoto Y., Ishimori T., Fujimoto K., Doi R. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—Usefulness and limitations in “clinical reality”. Ann. Nucl. Med. 2003; 17 (4): 261–279.Higashi T., Saga T., Nakamoto Y., Ishimori T., Fujimoto K., Doi R. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET)—Usefulness and limitations in “clinical reality”. Ann. Nucl. Med. 2003; 17 (4): 261–279.Kauhanen S.P., Komar G., Seppänen M.P., Dean K.I., Minn H.R., Kajander S.A. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009; 250 (6): 957–963. DOI: 10.1097/SLA.0b013e3181b2fafa.Kauhanen S.P., Komar G., Seppänen M.P., Dean K.I., Minn H.R., Kajander S.A. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009; 250 (6): 957–963. DOI: 10.1097/SLA.0b013e3181b2fafa.Dibble E.H., Karantanis D., Mercier G., Peller P.J., Kachnic L.A., Subramaniam R.M. PET/CT of cancer patients: part 1, pancreatic neoplasms. Am. J. Roentgenol. 2012; 199 (5): 952–967. DOI: 10.2214/AJR.11.8182.Dibble E.H., Karantanis D., Mercier G., Peller P.J., Kachnic L.A., Subramaniam R.M. PET/CT of cancer patients: part 1, pancreatic neoplasms. Am. J. Roentgenol. 2012; 199 (5): 952–967. DOI: 10.2214/AJR.11.8182.Lyshchik A., Higashi T., Hara T., Nakamoto Y., Fujimoto K., Doi R. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007; 25 (3): 154–162. DOI: 10.1080/07357900701208931.Lyshchik A., Higashi T., Hara T., Nakamoto Y., Fujimoto K., Doi R. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007; 25 (3): 154–162. DOI: 10.1080/07357900701208931.Nishiyama Y., Yamamoto Y., Monden T., Sasakawa Y., Tsutsui K., Wakabayashi H. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl. Med. Commun. 2005; 26 (10): 895–901.Nishiyama Y., Yamamoto Y., Monden T., Sasakawa Y., Tsutsui K., Wakabayashi H. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl. Med. Commun. 2005; 26 (10): 895–901.Bares R., Klever P., Hauptmann S., Hellwig D., Fass J., Cremerius U. 18F-fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994; 192 (1): 79–86. DOI: 10.1148/radiology.192.1.8208970.Bares R., Klever P., Hauptmann S., Hellwig D., Fass J., Cremerius U. 18F-fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994; 192 (1): 79–86. DOI: 10.1148/radiology.192.1.8208970.Ruf J., Hänninen E. L., Böhmig M., Koch I., Denecke T., Plotkin M. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology. 2006; 6 (6): 512–519. DOI: 10.1159/000096993.Ruf J., Hänninen E. L., Böhmig M., Koch I., Denecke T., Plotkin M. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology. 2006; 6 (6): 512–519. DOI: 10.1159/000096993.Wang X., Yu L. J. 18F-FDG PET/CT in detection of pancreatic cancer: Value of synthetic analysis interpretation. Zhongguo Yixue Yingxiang Jishu. 2007; 23: 1709–1712.Wang X., Yu L. J. 18F-FDG PET/CT in detection of pancreatic cancer: Value of synthetic analysis interpretation. Zhongguo Yixue Yingxiang Jishu. 2007; 23: 1709–1712.Hillner B.E., Siegel B.A., Liu D., Shields A.F., Gareen I.F., Hanna L. Impact of positron emission tomography/ computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J. Clin. Oncol. 2008; 26 (13): 2155–2161. DOI: 10.1200/JCO.2007.14.5631.Hillner B.E., Siegel B.A., Liu D., Shields A.F., Gareen I.F., Hanna L. Impact of positron emission tomography/ computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J. Clin. Oncol. 2008; 26 (13): 2155–2161. DOI: 10.1200/JCO.2007.14.5631.Wang Z., Chen J. Q., Liu J. L., Qin X. G., Huang, Y. FDGPET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. Wld J. Gastroenterol. 2013; 19 (29): 4808. DOI: 10.3748/wjg.v19.i29.4808.Wang Z., Chen J. Q., Liu J. L., Qin X. G., Huang, Y. FDGPET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. Wld J. Gastroenterol. 2013; 19 (29): 4808. DOI: 10.3748/wjg.v19.i29.4808.Nakata B., Nishimura S., Ishikawa T., Ohira M., Nishino H., Kawabe J. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int. J. Oncol. 2001; 19 (1): 53–58.Nakata B., Nishimura S., Ishikawa T., Ohira M., Nishino H., Kawabe J. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int. J. Oncol. 2001; 19 (1): 53–58.Lyshchik A., Higashi T., Nakamoto Y., Fujimoto K., Doi R., Imamura M., Saga T. Dual-phase 18F-fluoro-2-deoxy-Dglucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (4): 389–397. DOI: 10.1007/s00259-004-1656-0.Lyshchik A., Higashi T., Nakamoto Y., Fujimoto K., Doi R., Imamura M., Saga T. Dual-phase 18F-fluoro-2-deoxy-Dglucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (4): 389–397. DOI: 10.1007/s00259-004-1656-0.Topkan E., Parlak C., Kotek A., Yapar A. F., Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011; 11 (1): 123. DOI: 10.1186/1471-230X-11-123.Topkan E., Parlak C., Kotek A., Yapar A. F., Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011; 11 (1): 123. DOI: 10.1186/1471-230X-11-123.Heinrich S., Goerres G.W., Schäfer M., Sagmeister M., Bauerfeind P., Pestalozzi B.C. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 2005; 242 (2): 235–243.Heinrich S., Goerres G.W., Schäfer M., Sagmeister M., Bauerfeind P., Pestalozzi B.C. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 2005; 242 (2): 235–243.Coleman R.E., DeGrado T.R., Wang S., Baldwin S.W., Orr M.D., Reiman R.E., Price D.T. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent. Clin. Positron Imaging. 2000; 3 (4): 147.Coleman R.E., DeGrado T.R., Wang S., Baldwin S.W., Orr M.D., Reiman R.E., Price D.T. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent. Clin. Positron Imaging. 2000; 3 (4): 147.Wang X.Y., Yang F., Jin C., Fu D.L. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. Wld J. Gastroenterol. 2014; 20 (42): 15580–15589. DOI: 10.3748/wjg.v20.i42.15580.Wang X.Y., Yang F., Jin C., Fu D.L. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. Wld J. Gastroenterol. 2014; 20 (42): 15580–15589. DOI: 10.3748/wjg.v20.i42.15580.Nishiyama Y., Yamamoto Y., Monden T., Sasakawa Y., Tsutsui K., Wakabayashi H., Ohkawa M. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl. Med. Communications. 2005; 26 (10): 895–901.Nishiyama Y., Yamamoto Y., Monden T., Sasakawa Y., Tsutsui K., Wakabayashi H., Ohkawa M. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl. Med. Communications. 2005; 26 (10): 895–901.Tann M., Sandrasegaran K., Jennings S.G., Skandarajah A., McHenry L., Schmidt C.M. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin. Radiol. 2007; 62 (8): 745–751. DOI: 10.1016/j.crad.2007.01.023.Tann M., Sandrasegaran K., Jennings S.G., Skandarajah A., McHenry L., Schmidt C.M. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin. Radiol. 2007; 62 (8): 745–751. DOI: 10.1016/j.crad.2007.01.023.Takakura K., Sumiyama K., Munakata K., Ashida H., Arihiro S., Kakutani H., Tajiri H. Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT. Abdom. Imaging. 2011; 36 (4): 457–462. DOI: 10.1007/s00261-011-9728-7.Takakura K., Sumiyama K., Munakata K., Ashida H., Arihiro S., Kakutani H., Tajiri H. Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT. Abdom. Imaging. 2011; 36 (4): 457–462. DOI: 10.1007/s00261-011-9728-7.Neoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., Fernandez-Cruz L. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358 (9293): 1576–1585.Neoptolemos J.P., Dunn J.A., Stocken D.D., Almond J., Link K., Beger H., Fernandez-Cruz L. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358 (9293): 1576–1585.Ford E.C., Herman J., Yorke E., Wahl R.L. 18F-FDG PET/ CT for image-guided and intensity-modulated radiotherapy. J. Nucl. Med. 2009; 50 (10): 1655–1665. DOI: 10.2967/jnumed.108.055780.Ford E.C., Herman J., Yorke E., Wahl R.L. 18F-FDG PET/ CT for image-guided and intensity-modulated radiotherapy. J. Nucl. Med. 2009; 50 (10): 1655–1665. DOI: 10.2967/jnumed.108.055780.Topkan E., Yavuz A.A., Aydin M., Onal C., Yapar F., Yavuz M.N. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J. Experim. & Clin. Cancer Res. 2008; 27 (1): 41. DOI: 10.1186/1756-9966-27-41.Topkan E., Yavuz A.A., Aydin M., Onal C., Yapar F., Yavuz M.N. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J. Experim. & Clin. Cancer Res. 2008; 27 (1): 41. DOI: 10.1186/1756-9966-27-41.Rose D.M., Delbeke D., Beauchamp R.D., Chapman W.C., Sandler M.P., Sharp K.W., Leach S.D. 18-Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann. Surg. 1999; 229 (5): 729.Rose D.M., Delbeke D., Beauchamp R.D., Chapman W.C., Sandler M.P., Sharp K.W., Leach S.D. 18-Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann. Surg. 1999; 229 (5): 729.Bang S., Chung H.W., Park S.W., Chung J.B., Yun M., Lee J.D., Song S.Y. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J. Clin. Gastroenterol. 2006; 40 (10): 923–929. DOI: 10.1097/01.mcg.0000225672.68852.05.Bang S., Chung H.W., Park S.W., Chung J.B., Yun M., Lee J.D., Song S.Y. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J. Clin. Gastroenterol. 2006; 40 (10): 923–929. DOI: 10.1097/01.mcg.0000225672.68852.05.Ruf J., Hänninen E.L., Oettle H., Plotkin M., Pelzer U., Stroszczynski C., Amthauer H. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology. 2005; 5 (2): 266–272. DOI: 10.1159/000085281.Ruf J., Hänninen E.L., Oettle H., Plotkin M., Pelzer U., Stroszczynski C., Amthauer H. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology. 2005; 5 (2): 266–272. DOI: 10.1159/000085281.Michl P., Pauls S., Gress T.M. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006; 20 (2): 227–251. DOI: 10.1016/j.bpg.2005.10.005.Michl P., Pauls S., Gress T.M. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006; 20 (2): 227–251. DOI: 10.1016/j.bpg.2005.10.005.Goh B.K., Chung Y.F., Ng D.C., Selvarajan S., Soo K.C. Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP. 2007; 8 (3): 350–354.Goh B.K., Chung Y.F., Ng D.C., Selvarajan S., Soo K.C. Positron emission tomography with 2-deoxy-2-[18f] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP. 2007; 8 (3): 350–354.Langer A.A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a costeffective manner? BMC Health Services Res. 2010; 10 (1): 283. DOI: 10.1186/1472-6963-10-283.Langer A.A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a costeffective manner? BMC Health Services Res. 2010; 10 (1): 283. DOI: 10.1186/1472-6963-10-283.Segard T., Robins P.D., Yusoff I.F., Ee H., Morandeau L., Campbell E.M., Francis R.J. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspectedor proven pancreatic cancer. Clin. Nucl. Med. 2013; 38 (1): 1–6. DOI: 10.1097/RLU.0b013e3182708777.Segard T., Robins P.D., Yusoff I.F., Ee H., Morandeau L., Campbell E.M., Francis R.J. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspectedor proven pancreatic cancer. Clin. Nucl. Med. 2013; 38 (1): 1–6. DOI: 10.1097/RLU.0b013e3182708777.Herrmann K., Erkan M., Dobritz M., Schuster T., Siveke J.T., Beer A.J., Kleeff J. Comparison of 3′-deoxy3′-[18F] fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (5): 846–851. DOI: 10.1007/s00259-012-2061-8.Herrmann K., Erkan M., Dobritz M., Schuster T., Siveke J.T., Beer A.J., Kleeff J. Comparison of 3′-deoxy3′-[18F] fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (5): 846–851. DOI: 10.1007/s00259-012-2061-8.Henriksen G., Herz M., Hauser A., Schwaiger M., Wester H.J. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F] fluorocholine ([18F] dOC). Nucl. Med. Biol. 2004; 31 (7): 851–858.Henriksen G., Herz M., Hauser A., Schwaiger M., Wester H.J. Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F] fluorocholine ([18F] dOC). Nucl. Med. Biol. 2004; 31 (7): 851–858.Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Evans D.B. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008; 26 (18): 3063–3072. DOI: 10.1200/JCO.2007.15.4377.Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Evans D.B. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 2008; 26 (18): 3063–3072. DOI: 10.1200/JCO.2007.15.4377.Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO classification of tumours of the digestive system. Wld Health Organization. 2010; 4.Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO classification of tumours of the digestive system. Wld Health Organization. 2010; 4.Krenning E.P., Kwekkeboom D.J., Bakker W.E.A., Breeman W.A.P., Kooij P.P.M., Oei H.Y., Visser T.J. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993; 20 (8): 716–731. DOI:10.1007/BF00181765.Krenning E.P., Kwekkeboom D.J., Bakker W.E.A., Breeman W.A.P., Kooij P.P.M., Oei H.Y., Visser T.J. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993; 20 (8): 716–731. DOI:10.1007/BF00181765.Srirajaskanthan R., Kayani I., Quigley A.M., Soh J., Caplin M.E., Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J. Nucl. Med. 2010; 51 (6): 875–882. DOI: 10.2967/jnumed.109.066134.Srirajaskanthan R., Kayani I., Quigley A.M., Soh J., Caplin M.E., Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J. Nucl. Med. 2010; 51 (6): 875–882. DOI: 10.2967/jnumed.109.066134.Schreiter N.F., Brenner W., Nogami M., Buchert R., Huppertz A., Pape U.F., Prasad V., Hamm B., Maurer M. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (1): 72–82. DOI: 10.1007/s00259-011-1935-5.Schreiter N.F., Brenner W., Nogami M., Buchert R., Huppertz A., Pape U.F., Prasad V., Hamm B., Maurer M. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (1): 72–82. DOI: 10.1007/s00259-011-1935-5.Ambrosini V., Campana D., Bodei L., Nanni C., Castellucci P., Allegri V., Fanti S. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J. Nucl. Med. 2010; 51 (5): 669–673. DOI: 10.2967/jnumed.109.071712.Ambrosini V., Campana D., Bodei L., Nanni C., Castellucci P., Allegri V., Fanti S. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J. Nucl. Med. 2010; 51 (5): 669–673. DOI: 10.2967/jnumed.109.071712.Ambrosini V., Campana D., Tomassetti P., Fanti S. 68Galabelled peptides for diagnosis of gastroenteropancreatic NET. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (1): 52–60. DOI:10.1007/s00259-011-1989-4.Ambrosini V., Campana D., Tomassetti P., Fanti S. 68Galabelled peptides for diagnosis of gastroenteropancreatic NET. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (1): 52–60. DOI:10.1007/s00259-011-1989-4.Koopmans K.P., de Vries E.G., Kema I.P., Elsinga P.H., Neels O.C., Sluiter W.J., Jager P.L. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006; 7 (9): 728–734.Koopmans K.P., de Vries E.G., Kema I.P., Elsinga P.H., Neels O.C., Sluiter W.J., Jager P.L. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006; 7 (9): 728–734.Kayani I., Conry B.G., Groves A.M., Win T., Dickson J., Caplin M., Bomanji J.B. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 2009; 50 (12): 1927–1932. DOI: 10.1016/S1470-2045(06)70801-4.Kayani I., Conry B.G., Groves A.M., Win T., Dickson J., Caplin M., Bomanji J.B. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 2009; 50 (12): 1927–1932. DOI: 10.1016/S1470-2045(06)70801-4.Pasquali C., Rubello D., Sperti C., Gasparoni P., Liessi G., Chierichetti F., Pedrazzoli S. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? Wld J. Surg. 1998; 22 (6): 588–592.Pasquali C., Rubello D., Sperti C., Gasparoni P., Liessi G., Chierichetti F., Pedrazzoli S. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? Wld J. Surg. 1998; 22 (6): 588–592.Binderup T., Knigge U., Loft A., Federspiel B., Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 2010; 16 (3): 978–985. DOI: 10.1158/1078-0432.CCR-09-1759.Binderup T., Knigge U., Loft A., Federspiel B., Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 2010; 16 (3): 978–985. DOI: 10.1158/1078-0432.CCR-09-1759.

The authors declare that there are no conflicts of interest present.